Skip to content

For US Healthcare Professionals Only

Prescribing Information
Patient Site
Vevye Logo Vevye Logo Contact Us

WELL-TOLERATED By Patients 1,5-7

VEVYE® is shown to be well-tolerated and comfortable with 8% of patients experiencing site instillation reactions and 3% reporting a temporary decrease in visual acuity.

WELL-TOLERATED By Patients 1,5-7 By Patients 1,5-7

VEVYE® is shown to be well-tolerated and comfortable with 8% of patients experiencing site instillation reactions and 3% reporting a temporary decrease in visual acuity.

99.8% of patients experienced no or
mild instillation site pain 5-7

*Total number of patients in pooled data: 785.

99.8% of patients

experienced no or
mild instillation
site pain 5-7*

*Total number of patients in pooled data: 785.

Common Adverse Reactions 1,5-7

Ocular AEs (Occurring in More Than 2% of Patients)

Swipe to view More

Over 3 studies,

VEVYE® (cyclosporine ophthalmic solution) 0.1% had ZERO reports of severe instillation site pain. 5‑7

Most common adverse reactions included instillation site reactions (8%) and temporary decrease in visual acuity (3%). 

In a 52-week extension study

Only 1 patient discontinued treatment

due to an ocular adverse event (mild burning/stinging). (n=202) 7

Discontinuation Rates 4-7

Swipe to view More

**Treatment Emergent Adverse Event (TEAE) suspected to be related to VEVYE.

time to try vevye

Connect with a representative to learn more.

Connect with a representative to learn more.

Contact Us

INDICATION AND USAGE

VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
  • Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.

Adverse Reactions

In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional information about VEVYE, please see the Full Prescribing Information.